GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Fisher & Paykel Healthcare Corp Ltd (NZSE:FPH) » Definitions » Cash Conversion Cycle

Fisher & Paykel Healthcare (NZSE:FPH) Cash Conversion Cycle : 181.81 (As of Sep. 2023)


View and export this data going back to 1979. Start your Free Trial

What is Fisher & Paykel Healthcare Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Fisher & Paykel Healthcare's Days Sales Outstanding for the six months ended in Sep. 2023 was 46.72.
Fisher & Paykel Healthcare's Days Inventory for the six months ended in Sep. 2023 was 208.56.
Fisher & Paykel Healthcare's Days Payable for the six months ended in Sep. 2023 was 73.47.
Therefore, Fisher & Paykel Healthcare's Cash Conversion Cycle (CCC) for the six months ended in Sep. 2023 was 181.81.


Fisher & Paykel Healthcare Cash Conversion Cycle Historical Data

The historical data trend for Fisher & Paykel Healthcare's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fisher & Paykel Healthcare Cash Conversion Cycle Chart

Fisher & Paykel Healthcare Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 134.45 115.09 110.03 188.90 216.46

Fisher & Paykel Healthcare Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.17 160.48 209.57 168.10 181.81

Competitive Comparison of Fisher & Paykel Healthcare's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fisher & Paykel Healthcare's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Fisher & Paykel Healthcare's Cash Conversion Cycle falls into.



Fisher & Paykel Healthcare Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Fisher & Paykel Healthcare's Cash Conversion Cycle for the fiscal year that ended in Mar. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=38.17+205.78-27.49
=216.46

Fisher & Paykel Healthcare's Cash Conversion Cycle for the quarter that ended in Sep. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=46.72+208.56-73.47
=181.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fisher & Paykel Healthcare  (NZSE:FPH) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Fisher & Paykel Healthcare Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Fisher & Paykel Healthcare's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Fisher & Paykel Healthcare (NZSE:FPH) Business Description

Traded in Other Exchanges
Address
15 Maurice Paykel Place, East Tamaki, Auckland, NTL, NZL, 2013
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use humidifiers, masks and related consumables and the number three player in the at-home treatment of sleep apnoea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns 42% of its revenue in the U.S., 32% in Europe, 18% in Asia-Pacific and the remaining 8% in emerging markets. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand and Mexico and has a multichannel distribution model.